Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

I&I WC2 > Transplantation medicine > Flashcards

Transplantation medicine Flashcards

1
Q

Immunosuppresion after transplantation is a matter of balance between rejection & complications. What are the dangers of each? (2x2)

A

Rejection:
1. Graft failure
2. Graft dysfunction

Complication:
1. Malignancies
2. Infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What was an important factor allowing for a strong decrease in acute organ rejection over the past decades?

A

Introduction of calcineurin inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which drugs are calcineurin inhibitors? (2)

A
  1. Cyclosporine
  2. Tacrolimus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the effect of the introduction of calcineurin inhibitors on long-time graft survival?

A

No significant improvement -> beneficial effect of calcineurin inhibitors disappears after 1 year, after that, surival curves run parallel to old immunosuppressive regimen curves

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the most common cause of graft loss?

A

Death with functioning graft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the causes of death with functioning graft? How many % do they each comprise? (5)

A
  1. Cardiovascular: 34%
  2. Infection: 16%
  3. Malignancy: 15%
  4. GI/liver complications: 6%
  5. Other: 29%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

True or false: immunosuppression after transplantation increases the risk of some malignancies

A

False; (virtually) all malignancies are increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the most prevalent type of tumour in transplantation patients?

A

Skin cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How much is the risk of skin cancer elevated in Tx-recipients compared to normal population?

A

125x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which types of skin cancer are increased in Tx-recipients? (5)

A
  1. Melanoma
  2. Squamous cell carcinoma (SCC)
  3. Basal cell carcinoma (BCC)
  4. Kaposi sarcoma
  5. Merkel cell tumours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the risk factors for skin cancer in Tx-recipients? Are they different from non Tx-recipients?

A
  1. UV radiation
  2. Fair phenotypic features
  3. Geographic location
  4. History of SCC/BCC
  5. Viral infection: HHV8, HPV
  6. Genetic factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which genetic polymorphisms especially predispose for skin cancer?

A

Polymorphims in folate pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are Tx-specific risk factors for skin cancer (and cancer more generally)? (3)

A
  1. Age at transplantation
  2. Type of transplant
  3. Type, duration & intensity of immunosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the cumulative incidence of non-melanoma skin cancer (NMSC) in Tx-recipients after 5 and 20 years?

A

<5 years: 29%
>20 years: 82%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which skin cancer type behaves significantly different in skin cancer patients?

A

Squamous cell carcinoma -> more aggressive & invasive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Incidences of solid tumours post-Tx are not equal in every country and even differ between transplantation centres. What differentiates them? (4)

A
  1. Genetics
  2. Environmental conditions
  3. Patient population accepted for Tx
  4. Immunosuppressive regimens used
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How much increased are the odds of invasive solid tumours in Tx-recipients compared to the general population?

A

15,7x increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which types of cancer don’t have an increased incidence in Tx-recipients? (3) Why?

A
  1. Mamma
  2. Prostate
  3. Lung

These cancers already have a high incidence -> immunosuppression doesn’t excessively increase epidemiological risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How many years post-Tx do solid tumours typically occur?

A

~15 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Through which mechanisms do anti-T-cell therapies in Tx-patients contribute to malignancy?

A

Specific increase of virus-associated tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is an example of a tumour that can occur due to decreased T-cell surveillance due to immunosuppression in transplant patients?

A

EBV-related post-transplant lymphoproliferative disease (PTLD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How does EBV-related post-transplant lymphoproliferative disease (PTLD) develop? (3)

A
  1. EBV-infected cells are normally held in check by CD8+
  2. Immunosuppression reduced CD8+ surveillance, allowing expansion of EBV-infected B-cells
  3. PTLD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How can the risk of EBV-related post-transplant lymphoproliferative disease (PTLD) be lowered?

A

Addition of rituximab if anti-T-cell therapy is used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How is EBV-related post-transplant lymphoproliferative disease (PTLD) treated?

25
What determines the risk of EBV-related post-transplant lymphoproliferative disease (PTLD)?
EBV infection status pre-Tx: EBV+ pre-Tx = no increased risk EBV- post-Tx = increased risk upon EBV infection
26
In which instances are anti-T-cell therapies used in transplantation settings? (2)
1. Induction therapy 2. Acute T-cell mediated rejection
27
Which anti-T-cell therapies are used in transplantation settings? (2)
1. Alemtuzumab 2. Anti-thymocyte globulin (ATG)
28
How can the risk of EBV-related post-transplant lymphoproliferative disease (PTLD) due to induction therapy be lowered?
Using a non-T-cell suppressive induction therapy such as basiliximab in EBV- patients
29
Why is it difficult to observe the risk of malignancy due to immunosuppressive therapies in clinical trials?
Malignancies take a long time to develop -> require extremely long follow-up times
30
What are the pro-malignant effects of calcineurin inhibitors?
1. Increased levels of TGF-β: promotes tumour growth & invasive behaviour 2. Elevated VEGF-expression: pro-angiogenic effects 3. Increased levels of IL-6: predisposition to EBV-induced B-cell expansion
31
Calcineurin inhibitors give a stronger increase in [non-melanoma skin cancer/melanoma] than in [non-melanoma skin cancer/melamoma]
Non-melanoma skin cancer = stronger increase than melanoma
32
Which strategy is employed to reduce malignancy risks due to calcineurin inhibitors?
Measure through levels & taper immunosuppression as much as possible
33
Azathoprine was frequently used in post-Tx immunosuppression, but has largely been phased out. Why?
Replaced by calcineurin inhibitors
34
What is the mechanism of action of azathoprine?
Purine antagonist: inhibits DNA, RNA & protein synthesis & metabolism
35
What are the oncogenic effects of azathioprine?
1. Impaired DNA repair mechanisms 2. Photosensitization 3. Accumulation of 6-thioguanine in DNA -> produces ROS when exposed to UV-A
36
Which type of cancer is particularly increased by azathioprine?
Squamous cell carcinoma
37
What is the mechanism of action of mycophenolate mofetil?
Inhibition of inosine monophosphate dehydrogenase (IMDPH) in the de novo purine synthesis pathway -> suppression of T- and B-cell proliferation
38
What is the effect of mycophenolate mofetil on malignancy risk?
No additional risk of malignancy observed
39
True or false: patients with grafts from a DCD donor have a higher risk of malignancy than from DBD donors
False: DBD and DCD have equal risk
40
What is the general effect of post-Tx immunosuppression on malignancy prognosis?
Severely worse than age-matched peers
41
Why are patients receiving organ transplantation today more at risk of developing malignancy than patients from the 1990s?
More aggressive immunosuppressive regimens
42
Which drug was used before the introduction of calcineurin inhibitors?
Cyclosporine
43
Which 3 drugs form the standard immunosuppressive regimen after kidney transplantation? (3)
1. Tacrolimus 2. Mycophenolate mofetil (MMF) 3. Steroids (prednisone)
44
What are the side effects of prednisone (5)? How strong are these effects (-/+/++/+++)?
1. Hypertension: + 2. Hair growth: + 3. Increased cholsterol: + 4. Muscle weakness: + 5. Obesity/facial fat: ++
45
What are the side effects of tacrolimus? (6) How strong are these effects (-/+/++/+++)?
1. Hypertension: + 2. Hair growth: - 3. Diabetes mellitus/worsening: ++ 4. Nephrotoxicity: ++ 5. Neurotoxicity: + 6. Increased cholsterol: +
46
What are the side effects of cyclosporine? (6) How strong are these effects (-/+/++/+++)?
1. Hypertension: ++ 2. Hair growth: + 3. Diabetes mellitus/worsening: + 4. Nephrotoxicity: ++ 5. Neurotoxicity: + 6. Increased cholsterol
47
What are the side effects of azathioprine? (3) How strong are these effects (-/+/++/+++)?
1. Hepatotoxicity: ++ 2. Bone marrow toxicity: +++ 3. Abdominal complaints/diarrhoea: +
48
What are the side effects of mycophenolate mofetil? (2)How strong are these effects (-/+/++/+++)?
1. Bone marrow toxicity: ++ 2. Abdominal complaints/diarrhoea: +++
49
What are the side effects of sirolimus/everolimus? (6) How strong are these effects (-/+/++/+++)?
1. Nephrotoxicity: + 2. Ulcerations in the mouth: + 3. Increased cholsterol: ++ 4. Hepatotoxicity: + 5. Bone marrow toxicity: ++ 6. Abdominal complaints/diarrhoea: +
50
Which three groups of complications of kidney transplantation can occur? (3)
1. Complications around surgery 2. Side effects of immunosuppressive medication 3. Negative effects of immunosuppression
51
What are surgery-related complications of kidney transplantation? (4)
1. Thrombosis 2. Bleeding 3. Infection 4. Ureter obstruction/leakage
52
What are approaches to prevent post-Tx cancer?
1. Increased screening 2. Preventative strategies 3. Reactive strategies
53
Which adaptations are made in cancer screening post-Tx?
More frequent screening for cervival cancer (HPV test every year instead of every 5 years)
54
Which adaptations to cancer screening post-Tx are being considered? (2)
1. Yearly faecal occult blood test for CRC-screening (instead of every 2 years) 2. Starting CRC screening earlier (45 or 50 years instead or 55)
55
Which preventative strategy for post-Tx malignancies is being explored? Is this succesful?
Tapering of immunosuppression; database research of tapering of immunosuppression shows no survival benefit -> patients experience more graft loss
56
What are reactive strategies post-Tx malignancies? (2)
1. Tapering immunosuppression after cancer diagnosis 2. Switching to sirolimus/everolimus (for skin cancer)
57
For which cancer types is tapering of immunosuppression in Tx-recipients currently recommended? (2)
1. Lymphoma 2. Kaposi sarcoma
58
What is the benefit of switching to sirolimus/everolimus upon diagnosis of skin cancer in Tx-recipients?
Sirolimus/everolimus appears to reduce the risk of formation of new skin cancers to a (small) degree
59
What is the benefit of switching to sirolimus/everolimus upon diagnosis of skin cancer in Tx-recipients?
25% of patients do not tolerate this treatment

I&I WC2 (25 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions